Novyra Pharmachem shareholders and shareholding pattern
BSE: 519353Agricultural Food & other ProductsSmall Cap
NOVYRA PHARMACHEM LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1994
Last close ₹8.50down ₹0.21 (2.41%)
Share price at the BSE close on 13 Oct 2026. Previous close ₹8.71.
13 Oct: open ₹8.50, high ₹8.50, low ₹8.50
52-week range of traded prices to 13 Oct 2026
₹6.47Low, 13 Oct 2025₹16.55High, 23 Mar 2026
- Under BSE's graded surveillance, stage 0, on the list for 26 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 2 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5.38 Cr4,706th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −166.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −906.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 100
Novyra Pharmachem's shareholding pattern for Sep 2026, filed on 21 Oct 2026, with every filing from Dec 2016: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Novyra Pharmachem, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters23.15%
- Individuals and others76.85%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Individuals and others
| Per cent | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 26.64% | 26.64% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | |
| Indian promoters | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 35.42% | 26.64% | 26.64% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% | 23.15% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 64.58% | 64.58% | 64.58% | 64.58% | 64.58% | 64.58% | 64.58% | 64.58% | 64.58% | 73.36% | 73.36% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% | 76.85% |
| Shares in issue | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,300 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,29,900 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 | 63,30,000 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 22,41,900 | 22,41,900 | 22,41,900 | 22,41,900 | 22,41,900 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Promoters' shares locked in | 22,41,900 | 22,41,900 | 22,41,900 | 22,41,900 | 22,41,900 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state.
Novyra Pharmachem promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is BANSIDHAR MITRUKA AND SONS, 3.02%.
| Holder | |||
|---|---|---|---|
| BANSIDHAR MITRUKA AND SONSIndividuals and Hindu undivided families | 3.02% | 1,91,100 | 0 |
| S L AGARWAL AND SONSIndividuals and Hindu undivided families | 2.55% | 1,61,500 | 0 |
| AMIT MITRUKAIndividuals and Hindu undivided families | 1.79% | 1,13,600 | 0 |
| KAUSHALYA DEVI AGARWALIndividuals and Hindu undivided families | 1.25% | 79,400 | 0 |
| S K AGARWAL AND SONS (H.U.F)Individuals and Hindu undivided families | 1.08% | 68,500 | 0 |
| SAMAR LAL AGAEWALIndividuals and Hindu undivided families | 1.08% | 68,100 | 0 |
| INDRA DEVI AGARWALIndividuals and Hindu undivided families | 1.06% | 67,000 | 0 |
| SANDEEP KUMAR AGARWALIndividuals and Hindu undivided families | 1.00% | 63,500 | 0 |
| SUNIL AGARWALIndividuals and Hindu undivided families | 0.61% | 38,500 | 0 |
| HARISANKAR AGARWALIndividuals and Hindu undivided families | 0.51% | 32,000 | 0 |
| RAMLAL SHARMAIndividuals and Hindu undivided families | 0.47% | 30,000 | 0 |
| SAKUNTALA DEVI AGARWALIndividuals and Hindu undivided families | 0.36% | 22,600 | 0 |
No promoter shares are reported as pledged. In demat is the part of the holding kept electronically; the rest is paper certificates.
Largest public holders of Novyra Pharmachem, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEEPAKBHAI PRABHAKAR KAPREResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.68% | 1.68% | 1.68% | 1.68% | 1.68% |
| Hetal Shashank DoshiResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.67% | 1.67% | 1.67% | 1.67% | 1.67% |
| KAVYA DOSHIResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.63% | 1.63% | 1.63% | 1.63% | 1.63% |
| DOSHI TEJResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% |
| KINJALBEN SNEHALKUMAR SHAHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% |
| TAPASYA KAMALKUMAR SHETHResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.07% | 1.07% | 1.07% | 1.07% | 1.07% |
| MALJAK MARKResident individuals, over ₹2 lakh at face value | 1.68% | 1.68% | – | – | – | – | – | – | – | – | 1.68% | – | – | – | – | – | – | – | 1.68% | 1.68% | 1.68% | 1.68% | 1.68% | 1.68% | – | – | – | – | – |
| SABITRI T SANGMAResident individuals, over ₹2 lakh at face value | 1.67% | 1.67% | – | – | – | – | – | – | – | – | 1.67% | – | – | – | – | – | – | – | 1.67% | 1.67% | 1.67% | 1.67% | 1.67% | 1.67% | – | – | – | – | – |
| WELTHINGH R MARKResident individuals, over ₹2 lakh at face value | 1.63% | 1.63% | – | – | – | – | – | – | – | – | 1.63% | – | – | – | – | – | – | – | 1.63% | 1.63% | 1.63% | 1.63% | 1.63% | 1.63% | – | – | – | – | – |
| BANSIDHAR MITRUKA & OTHERSResident individuals, over ₹2 lakh at face value | 1.14% | 1.14% | – | – | – | – | – | – | – | – | 1.14% | – | – | – | – | – | – | – | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.62% | – | – | – | – | – |
| TULIKA AGARWALResident individuals, over ₹2 lakh at face value | 1.62% | 1.62% | – | – | – | – | – | – | – | – | 1.62% | – | – | – | – | – | – | – | 1.62% | 1.62% | 1.62% | 1.62% | 1.62% | 1.14% | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.